Information Provided By: 
Fly News Breaks for May 14, 2018
LIFE
May 14, 2018 | 11:06 EDT
Piper Jaffray analyst Edward Tenthoff noted that aTyr Pharma announced it is discontinuing its preclinical ORCA program due to lack of sufficient efficacy and making a 30% workforce reduction in order to focus on its lead candidate, ATYR1923. After removing his estimated value for resolaris and ORCA from his model, Tenthoff cut his price target on aTyr shares to $3. He maintains an Overweight rating on the stock.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
